NextCell Pharma AB (NXTCL) Stock Statistics & Valuation Metrics

NextCell Pharma AB has a market cap or net worth of €113.18M. The enterprise value is kr86.84M.

NextCell Pharma AB has 111,392,960 shares outstanding. The number of shares has decreased by -2.65% in one year.

NextCell Pharma AB’s return on equity (ROE) is -0.62 and return on invested capital (ROIC) is -60.45%.

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.

In the last 12 months, NextCell Pharma AB had revenue of 10.66M and earned -41.96M in profits. Earnings per share was -0.57.

In the last 12 months, operating cash flow was -36.91M and capital expenditures -1.57M, giving a free cash flow of -38.48M billion.

NextCell Pharma AB pays an annual dividend of ―, resulting in a dividend yield of ―

NextCell Pharma AB upcoming earnings date is ―, ―.

NextCell Pharma AB as a current ratio of 6.14, with Debt / Equity ratio of 0.00%

In the past 12 months, NextCell Pharma AB has paid 0.00 in taxes.

NextCell Pharma AB EV to EBITDA ratio is -1.12, with an EV/FCF ratio of -1.22.

NextCell Pharma AB has €26.34M in cash and marketable securities with kr0.00 in debt, giving a net cash position of -€26.34M billion.

Gross margin is -213.24%, with operating margin of -404.81%, and net profit margin of -393.45%.

The average price target for NextCell Pharma AB is ―, which is 11.43% higher than the current price. The consensus rating is ―